{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang C"],"funding":["The Science & Technology Development Fund of Tianjin Education Commission for Higher Education","The Science &amp; Technology Development Fund of Tianjin Education Commission for Higher Education"],"pagination":["867"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11264757"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(1)"],"pubmed_abstract":["<h4>Objective</h4>To evaluate the safety and efficacy of the granisetron transdermal delivery system (GTDS) combined with Dexamethasone for preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving Capecitabine plus Oxaliplatin (CapeOX) therapy.<h4>Design</h4>Open-label, prospective, multi-center phase II trial.<h4>Setting</h4>Three institutions.<h4>Participants</h4>Fifty-four patients scheduled to receive CapeOX chemotherapy.<h4>Interventions</h4>Participants received GTDS (3.1 mg applied to the upper arm 48 h before chemotherapy, replaced on day 5, and discarded on day 12) and Dexamethasone.<h4>Main outcome measures</h4>The primary endpoint was the complete control rate of CINV. Secondary endpoints included the duration of delayed complete control, complete control"],"journal":["BMC cancer"],"pubmed_title":["Prolonged administration of the granisetron transdermal delivery system reduces capecitabine plus oxaliplatin regimen induced nausea and vomiting."],"pmcid":["PMC11264757"],"funding_grant_id":["2021KJ204"],"pubmed_authors":["Sun L","Jiang Z","Li Y","Pan Z","Yan Z","Zhang J","Wang B","Wang C","Quan M","Lan L","Zhuang Y"],"additional_accession":[]},"is_claimable":false,"name":"Prolonged administration of the granisetron transdermal delivery system reduces capecitabine plus oxaliplatin regimen induced nausea and vomiting.","description":"<h4>Objective</h4>To evaluate the safety and efficacy of the granisetron transdermal delivery system (GTDS) combined with Dexamethasone for preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving Capecitabine plus Oxaliplatin (CapeOX) therapy.<h4>Design</h4>Open-label, prospective, multi-center phase II trial.<h4>Setting</h4>Three institutions.<h4>Participants</h4>Fifty-four patients scheduled to receive CapeOX chemotherapy.<h4>Interventions</h4>Participants received GTDS (3.1 mg applied to the upper arm 48 h before chemotherapy, replaced on day 5, and discarded on day 12) and Dexamethasone.<h4>Main outcome measures</h4>The primary endpoint was the complete control rate of CINV. Secondary endpoints included the duration of delayed complete control, complete control","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-06-01T20:37:45.481Z","creation":"2026-05-22T03:07:42.328Z"},"accession":"S-EPMC11264757","cross_references":{"pubmed":["39026165"],"doi":["10.1186/s12885-024-12616-9"]}}